Project description
Checking genes to diagnose infectious and inflammatory diseases
Arriving at any diagnosis is a complex process that involves numerous tasks, from taking an appropriate history of symptoms to conducting laboratory tests. For patients with suspected infection or inflammation, a definitive diagnosis is not always reached. The EU-funded DIAMONDS project will develop a new diagnostic classification of infectious and inflammatory diseases. This new approach, which the project calls 'personalised molecular signature diagnosis' (PMSD), will be based on the discriminatory ability of a minimal set of genes able to distinguish all common conditions simultaneously. Specifically, the project will develop a device to detect genes required for PMSD. It will do so in partnership with 22 hospitals in 11 EU countries and biotechnology groups in academia, SMEs and industry.
Objective
Our proposal will address the challenge of bringing personalised medicine into routine use in EU healthcare systems for diagnosis and treatment of common infectious and inflammatory diseases, which account for a up to a third of all medical encounters in primary care and hospital. The diagnostic process in clinical medicine has been based on recognition of a constellation of symptoms and clinical signs, supported by laboratory tests. However, a definitive diagnosis is currently made in only a minority of patients presenting to healthcare with suspected infection or inflammation. We have previously shown that individual infectious and inflammatory diseases are characterised by unique patterns of host gene expression, and that diagnosis of individual diseases can be based on small numbers of uniquely expressed genes. We propose a new diagnostic classification of infectious and inflammatory diseases, based on the discriminatory ability of a minimal set of genes, which is able to distinguish all common conditions simultaneously, an approach we call Personalised Molecular Signature Diagnosis (PMSD). In partnership with 22 hospitals in 11 EU countries, and biotechnology groups in academia, SMEs and industry, we will develop a device to detect genes required for PMSD. We will then undertake a large-scale pilot demonstration in diverse healthcare settings in Europe, to establish the benefit to patients, reduction in healthcare resource use, cost effectiveness and acceptability to patients and carers, of PMSD.
Fields of science
Programme(s)
Topic(s)
Funding Scheme
IA - Innovation actionCoordinator
SW7 2AZ LONDON
United Kingdom
See on map
Participants (31)
WC1E 7HT London
See on map
OX1 2JD Oxford
See on map
L69 7ZX Liverpool
See on map
NE1 7RU Newcastle Upon Tyne
See on map
NE7 7DN Newcastle-Upon-Tyne
See on map
CV4 7EZ Coventry
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1081 HV Amsterdam
See on map
3015 GD Rotterdam
See on map
Participation ended
6525 XZ Nijmegen
See on map
3584 CX Utrecht
See on map
3062 ME Rotterdam
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
80539 MUNCHEN
See on map
69117 Heidelberg
See on map
75012 Paris
See on map
69280 Marcy-l'Etoile
See on map
20122 Milano
See on map
00165 Roma
See on map
15703 Santiago De Compostela
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
15706 Santiago De Compostela
See on map
28046 MADRID
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
28041 Madrid
See on map
8010 Graz
See on map
8010 Graz
See on map
10561 Athina
See on map
1007 Riga
See on map
1000 Ljubljana
See on map
3012 Bern
See on map
3010 Melbourne
See on map
701 Tainan
See on map
8006 Zurich
See on map
6525 GA Nijmegen
See on map